RT Journal Article
SR Electronic
T1 Antibodies to <em>Aedes aegypti</em> D7L salivary proteins as a new serological tool to estimate human exposure to <em>Aedes</em> mosquitoes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.22.23300438
DO 10.1101/2023.12.22.23300438
A1 Chea, Sophana
A1 Willen, Laura
A1 Nhek, Sreynik
A1 Ly, Piseth
A1 Tang, Kristina
A1 Oristian, James
A1 Salas-Carrillo, Roberto
A1 Ponce, Aiyana
A1 Leon, Paola Carolina Valenzuela
A1 Kong, Dara
A1 Ly, Sokna
A1 Sath, Ratanak
A1 Lon, Chanthap
A1 Leang, Rithea
A1 Huy, Rekol
A1 Yek, Christina
A1 Valenzuela, Jesus G.
A1 Calvo, Eric
A1 Manning, Jessica E.
A1 Oliveira, Fabiano
YR 2023
UL http://medrxiv.org/content/early/2023/12/24/2023.12.22.23300438.abstract
AB Introduction Aedes spp. are the most prolific mosquito vectors in the world. Found on every continent, they can effectively transmit various arboviruses, including the dengue virus which continues to cause outbreaks worldwide and is spreading into previously non-endemic areas. The lack of widely available dengue vaccines accentuates the importance of targeted vector control strategies to reduce the dengue burden. High-throughput sensitive tools to estimate human-mosquito contact and evaluate vector control interventions are lacking. We propose a novel serological tool that allows rapid screening of large human cohorts for exposure to potentially infectious mosquitoes and effective targeting of vector control.Methods We tested 563 serum samples from a longitudinal pediatric cohort study previously conducted in Cambodia. Children enrolled in the study were dengue-naïve at baseline and were followed biannually for dengue incidence for two years. We used Western blotting and enzyme-linked immunosorbent assays to identify the most immunogenic Aedes aegypti salivary proteins and measure total anti-Ae. Aegypti IgG.Results We found a strong correlation (rs=0.86) between the combined IgG responses against AeD7L1 and AeD7L2 recombinant proteins and those to whole salivary gland homogenate. We observed seasonal fluctuations of AeD7L1+2 IgG responses, corresponding to Aedes spp. abundance in the region, and no cross-reactivity with Culex quinquefasciatus and Anopheles dirus mosquitoes. The baseline median AeD7L1+2 IgG responses for young children were higher in those who developed asymptomatic dengue versus those who developed symptomatic dengue.Conclusion The IgG response against AeD7L1+2 recombinant proteins is a highly sensitive and Aedes specific marker of human exposure to Aedes bites that can facilitate standardization of future serosurveys and epidemiological studies by its ability to provide a robust estimation of human-mosquito contact in a high-throughput fashion.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (Rockville, USA)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the USA National Institutes of Health and Cambodian National Ethics Committee on Human Research gave ethical approval for this work. ClinicalTrials.gov identifier: NCT03534245, ClinicalTrials.gov identifier: NCT00001846I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors